TAVR is noninferior to SAVR when treating low-risk patients, according to new data presented at ACC.24. In fact, it is associated with multiple benefits over surgery.

"This was an unneeded burden, which was solely adding to the administrative hassles of medicine," said American Society of Nuclear Cardiology President Larry Phillips.

Interventional cardiologist Foluso Fakorede, MD, opened a practice in rural Mississippi, the epicenter of the PAD and CLI epidemic, to try and reverse the glaring health disparities in that region.

See What’s New:

NRC is teaming with Connecticut-based Stamford Health to open a new outpatient center with improved efficiency and competitive pricing. 

Both S&P and Moody’s highlighted the Los Angeles-based company's strong revenue growth, competitive position and solid liquidity. 

Two-fifths of leaders at academic medical centers, 41%, see reducing average length of patient stay as far and away the No. 1 “most untapped” strategy to turn around falling operating margins.

“This is the first time in a very long time that we have a positive study for managing cardiogenic shock,” one cardiologist said. 

The SMART trial included one-year data from TAVR patients randomized to receive either a self-expanding Evolut valve or a balloon-expandable Sapien 3 valve. All patients presented with symptomatic severe aortic stenosis and a small aortic annulus. A whopping 87% of participants were women. 

The new research, based on data from more than 600 patients, was presented at ACC.24 in Atlanta and published in the New England Journal of Medicine. Semaglutide is sold by Novo Nordisk under the brand name Wegovy.